The NOICH Study.

Completed

• Conditions: Fetal or Neonatal Alloimmune Thrombocytopenia

• Registration Number: NL-OMON21014
• Lead Sponsor: Sanquin Bloodbank Amsterdam provides the trial medication

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 212

Inclusion Criteria

1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunization who have given birth to a child with a platelet count < 150 x 10 9/l in the first week of life;

2. HPA alloimmunization must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the fetus or homozygous partner;

Exclusion Criteria

1. Pregnant women with autoimmune thrombocytopenia;

2. Twins or multiple pregnancies;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of neonates with intracranial hemorrhage.

Secondary Outcome Measures

Name	Time	Method
Cord blood platelet count at birth.<br /><br>Other variables studied will be the levels of maternal and neonatal anti-HPA antibodies and IgG, the occurrence of other bleedings in the neonate as well as the necessity and type of neonatal treatment.